Glen Williams
Keine laufenden Positionen mehr
Profil
Glen Williams was a Vice President of Manufacturing at Biogen, Inc. He was also a Senior Vice President at Biolex Therapeutics, Inc. and a Senior Vice President of Global Technical Operations at Synageva BioPharma Corp.
Mr. Williams holds a Master's in Business Administration from Central Michigan University and an undergraduate degree from The Ohio State University.
Ehemalige bekannte Positionen von Glen Williams
| Unternehmen | Position | Ende |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | - |
| SYNAGEVA BIOPHARMA CORP | Technik-/Wissenschafts-/F&E-Leiter | - |
Biolex Therapeutics, Inc.
 Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Corporate Officer/Principal | - |
Ausbildung von Glen Williams
| Central Michigan University | Masters Business Admin |
| The Ohio State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC. | Distribution Services |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
